Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
about
The β-Lactams Strike Back: Ceftazidime-AvibactamIdentification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.Population pharmacokinetic analysis of piperacillin in burn patientsPulmonary penetration of piperacillin and tazobactam in critically ill patients.In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapyClinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella speciesEfficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions.Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusionsExpression of the AsbA1, OXA-12, and AsbM1 beta-lactamases in Aeromonas jandaei AER 14 is coordinated by a two-component regulon.Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases.Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
P2860
Q26796425-7F8E3DBD-35A3-4DFC-83BA-609D983A5E34Q33559047-49E066A0-5BF6-470F-8207-B7C007ACDA0CQ33798377-7E0947C4-612D-425E-8BB8-2096C696DB2AQ34216623-06D4C714-D5C5-45B4-8649-B591D0295B62Q34320027-84458CA9-85DE-438D-BD1D-77AD02173FBBQ34462071-4A522A23-D694-4FCB-A4CA-97108BA3F1A2Q34680546-AA29403F-DE31-44C9-B0B5-79C78C6A3562Q35128789-88A0DAA1-0E77-4E08-B428-A8C201814892Q35134525-2A7D16D6-4ABD-48D0-AF08-5B90A1D9F833Q36158212-1A7797B0-367A-4C4E-AA54-474BBBB513FFQ36439015-A3EE9E98-9D00-47C0-9140-C9EF7823AF62Q36730017-A25173D4-C802-4810-B021-F0DB612BB4D7Q37625193-4A10328D-C975-4433-A4F7-AB5D174C7FEFQ38664871-D9831A44-BAD4-4BE7-BDF9-80869563D177Q39001350-5403D807-12B5-4D6D-8E22-2F64B35C31CFQ39120027-A38B1A25-3EDA-443C-99B5-F2D9152ACBCBQ39783646-8979C7F5-C623-4701-8C26-A52C9EC869A7Q39844968-6359BEA5-60B2-4D9B-A4DE-CEB758925D52Q40288977-0C3C5954-00B5-4A1A-8715-4B4681A7996DQ40325943-B8F340BD-2C1E-4E53-A6F7-040D6A6B40C1Q40389902-DE1D87A8-3E02-447F-AF43-FC327A531A34Q41139120-1642BDE1-705F-4150-8A36-48794ADCCA78Q42109987-50A14A62-8BBE-4D2C-8CA2-4B7E6F13EF99Q43085417-06EB6D60-B946-4673-8979-9FDE8AAD9F31
P2860
Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
description
1994 nî lūn-bûn
@nan
1994 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Pharmacodynamics of piperacill ...... n in vitro model of infection.
@ast
Pharmacodynamics of piperacill ...... n in vitro model of infection.
@en
type
label
Pharmacodynamics of piperacill ...... n in vitro model of infection.
@ast
Pharmacodynamics of piperacill ...... n in vitro model of infection.
@en
prefLabel
Pharmacodynamics of piperacill ...... n in vitro model of infection.
@ast
Pharmacodynamics of piperacill ...... n in vitro model of infection.
@en
P2093
P2860
P356
P1476
Pharmacodynamics of piperacill ...... n in vitro model of infection.
@en
P2093
Gilbert DH
Medeiros AA
Pivarnik P
Strayer AH
P2860
P304
P356
10.1128/AAC.38.10.2351
P407
P577
1994-10-01T00:00:00Z